Coronavirus (COVID-19)
Learn more
A Phase II Trial of the PD-1 Antibody Nivolumab in Combination With Hypofractionated Re-irradiation and Bevacizumab for Recurrent MGMT Methylated Glioblastoma
This study is being done to see if adding nivolumab to radiation therapy and bevacizumab can increase the effectiveness of the treatment for recurrent glioblastoma.
Eligibility Criteria:
Available at: Hartford Hospital
Get the latest healthcare news directly in your inbox.
Sign up for text alerts / Text MoreLife to 31996.